Skip to main content
  • Site Staff Website Access Request Form
  • Connect With Us
  • Login

Search form

Home
  • About BMT CTN
    • What We Do
    • Why We Do What We Do
    • Who’s Involved
    • Clinical Centers
    • Enrollment in BMT CTN Studies
    • Our Annual Progress Report
    • Publications
    • State of the Science Symposia
    • Our History
    • Study Summaries for Patients
  • BMT CTN Studies
  • Investigator & Research Staff Resources
    • Overview
    • Administrative Manual of Procedures (MOP)/Policy Guidelines
    • Center Membership & Study Participation
    • Resources for Research Coordinators
    • Correlative Study Proposals
    • Funding Opportunities
    • Technical and Administrative Committees
    • Author Resources
  • Partner With Us

Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.

TitleImmune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial.
Publication TypeJournal Article
Year of Publication2021
AuthorsShindiapina, P, Pietrzak, M, Seweryn, M, McLaughlin, E, Zhang, X, Makowski, M, Ahmed, EHassan, Schlotter, S, Pearson, R, Kitzler, R, Mozhenkova, A, Le-Rademacher, J, Little, RF, Akpek, G, Ayala, E, Devine, SM, Kaplan, LD, Noy, A, Popat, UR, Hsu, JW, Morris, LE, Mendizabal, AM, Krishnan, A, Wachsman, W, Williams, N, Sharma, N, Hofmeister, CC, Forman, SJ, Navarro, WH, Alvarnas, JC, Ambinder, RF, Lozanski, G, Baiocchi, RA
JournalFront Immunol
Volume12
Pagination700045
Date Published2021
ISSN1664-3224
KeywordsClinical Trials, Phase II as Topic, Hematopoietic Stem Cell Transplantation, HIV Infections, Humans, Immune Reconstitution, Lymphoma, AIDS-Related, Transplantation, Autologous
Abstract

We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days post-AHCT, and 71 healthy control subjects. Principal component analysis showed that immune cell composition in HIV(+) and HIV(-) AHCT recipients clustered away from healthy controls and from each other at each time point, but approached healthy controls over time. Unsupervised feature importance score analysis identified activated T cells, cytotoxic memory and effector T cells [higher in HIV(+)], and naïve and memory T helper cells [lower HIV(+)] as a having a significant impact on differences between HIV(+) AHCT recipient and healthy control lymphocyte composition (p

DOI10.3389/fimmu.2021.700045
Alternate JournalFront Immunol
PubMed ID34539628
PubMed Central IDPMC8446430
Grant ListU01 CA121947 / CA / NCI NIH HHS / United States
U10 HL069294 / HL / NHLBI NIH HHS / United States
T32 CA009338 / CA / NCI NIH HHS / United States
P30 CA016058 / CA / NCI NIH HHS / United States
UM1 CA121947 / CA / NCI NIH HHS / United States
T32 CA090223 / CA / NCI NIH HHS / United States
  • Google Scholar
  • PubMed
  • DOI

Blood & Marrow Transplant Clinical Trials Network (BMT CTN)

Blood and Marrow Transplant Clinical Trials Network Twitter

Copyright © 2023, The Emmes Company LLC